연구동향 분석

ORiginal Article : The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea

( Kwang Hyun Chung ) ( Dong Ho Lee ) ( Eunhyo Jin ) ( Yuri Cho ) ( Ji Yeon Seo ) ( Nayoung Kim ) ( Sook Hyang Jeong ) ( Jin Wook Kim ) ( Jin Hyeok Hwang ) ( Cheol Min Shin ) 2014년

논문상세정보
인용/피인용
' ORiginal Article : The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 기초의학
  • anti- bacterial agents
  • helicobacter pylori
  • moxifloxacin
  • salvage therapy
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
960 0

0.0%

' ORiginal Article : The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea' 의 참고문헌

  • 한국인의 위·십이지장 질환에 따른 Helicobacter pylori 균주의 일차 항생제 내성과 H. pylori 제균율
    김재연 대한소화기학회지 58 (2) : 74 ~ 81 [2011]
  • Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study
    Oh HS J Gastroenterol Hepatol 27 : 504 ~ 509 - [2012]
  • Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure
    Gisbert JP Aliment Pharmacol Ther 23 : 35 ~ 44 - [2006]
  • Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure
    De Francesco V Aliment Pharmacol Ther 19 : 407 ~ 414 [2004]
  • Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan
    Tsay FW J Gastroenterol Hepatol 27 : 498 ~ 503 - [2012]
  • Secondline treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial
    Bago J Wien Klin Wochenschr 121 : 47 ~ 52 - [2009]
  • Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy
    Kang JM Helicobacter 12 : 623 ~ 628 - [2007]
  • Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies
    Chan FK Aliment Pharmacol Ther 14 : 91 ~ 95 - [2000]
  • Review article: Helicobacter pylori “rescue”regimen when proton pump inhibitor-based triple therapies fail
    Gisbert JP Aliment Pharmacol Ther 16 : 1047 ~ 1057 - [2002]
  • Recent developments in the epidemiology of Helicobacter pylori
    Everhart JE Gastroenterol Clin North Am 29 : 559 ~ 578 - [2000]
  • Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children
    Liu G Helicobacter 16 : 356 ~ 362 - [2011]
  • Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection
    Hojo M Scand J Gastroenterol 36 : 690 ~ 700 - [2001]
  • Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea
    Lee JW Helicobacter 16 : 301 ~ 310 - [2011]
  • Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection
    Kilic ZM Dig Dis Sci 53 : 3133 ~ 3137 - [2008]
  • Moxifloxacincontaining triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection:a meta-analysis
    Wu C Helicobacter 16 : 131 ~ 138 - [2011]
  • Moxifloxacin: a review of its use in the management of bacterial infections
    Keating GM Drugs 64 : 2347 ~ 2377 - [2004]
  • Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection:effect of treatment duration and antibiotic resistance on the eradication rate
    Yoon H Helicobacter 14 : 77 ~ 85 - [2009]
  • Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection
    Nista EC Aliment Pharmacol Ther 21 : 1241 ~ 1247 - [2005]
  • Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing 'concomitant therapy' versus triple therapy for Helicobacter pylori eradication
    Essa AS Helicobacter 14 : 109 ~ 118 - [2009]
  • Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report
    Malfertheiner P Gut 61 : 646 ~ 664 - [2012]
  • Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population
    Sezgin O Helicobacter 12 : 518 ~ 522 - [2007]
  • Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis
    Saad RJ Am J Gastroenterol 101 : 488 ~ 496 - [2006]
  • High eradication rate of H. pylori with moxifloxacin-based treatment:a randomized controlled trial
    Bago P Wien Klin Wochenschr 119 : 372 ~ 378 - [2007]
  • Helicobacter pylori 일ㆍ이차 제균요법 실패 후Moxifloxacin 포함 삼제병합요법 시도
    천재희 대한소화기학회지 45 (2) : 111 ~ 117 [2005]
  • Epidemiology of Helicobacter pylori infection and public health implications
    Goh KL Helicobacter 16 (Suppl 1) : 1 ~ 9 - [2011]
  • Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection
    Cheon JH Helicobacter 11 : 46 ~ 51 - [2006]
  • Effect of Helicobacter pylori density on inflammatory activity in stomach
    Fareed R J Pak Med Assoc 50 : 148 ~ 151 [2000]
  • Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG)
    Malfertheiner P Eur J Gastroenterol Hepatol 9 : 1 ~ 2 - [1997]
  • Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial
    Bago J Ann Clin Microbiol Antimicrob 9 : 13 ~ - [2010]
  • Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis
    Li Y Wien Klin Wochenschr 122 : 413 ~ 422 - [2010]